{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Child+Safety",
    "query": {
      "intervention": "Child Safety"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1647,
    "total_pages": 165,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Child+Safety&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T16:43:44.990Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01009905",
      "title": "An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Growth Hormone Disorder",
        "Pituitary Dwarfism",
        "Hypopituitarism"
      ],
      "interventions": [
        {
          "name": "somatropin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 22960,
      "start_date": "2002-06-24",
      "completion_date": "2016-09-30",
      "has_results": false,
      "last_update_posted_date": "2017-04-12",
      "last_synced_at": "2026-09-05T16:43:44.990Z",
      "location_count": 1,
      "location_summary": "Plainsboro, New Jersey",
      "locations": [
        {
          "city": "Plainsboro",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01009905"
    },
    {
      "nct_id": "NCT05915026",
      "title": "A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Contrast Enhancement in Magnetic Resonance Imaging",
        "Children"
      ],
      "interventions": [
        {
          "name": "Gadoquatrane (BAY1747846)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "0 Years to 17 Years"
      },
      "enrollment_count": 105,
      "start_date": "2023-08-16",
      "completion_date": "2024-09-25",
      "has_results": true,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-09-05T16:43:44.990Z",
      "location_count": 3,
      "location_summary": "Indian Wells, California • Kansas City, Missouri • Charleston, South Carolina",
      "locations": [
        {
          "city": "Indian Wells",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05915026"
    },
    {
      "nct_id": "NCT03219164",
      "title": "Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization",
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "AZLI",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Months to 18 Years"
      },
      "enrollment_count": 149,
      "start_date": "2017-11-28",
      "completion_date": "2021-09-23",
      "has_results": true,
      "last_update_posted_date": "2022-06-14",
      "last_synced_at": "2026-09-05T16:43:44.990Z",
      "location_count": 12,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 8 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03219164"
    },
    {
      "nct_id": "NCT02132247",
      "title": "Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Athletic Injuries"
      ],
      "interventions": [
        {
          "name": "Diclofenac hydroxyethylpyrrolidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IBSA Institut Biochimique SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "6 Years to 16 Years"
      },
      "enrollment_count": 104,
      "start_date": "2014-05",
      "completion_date": "2017-05",
      "has_results": true,
      "last_update_posted_date": "2018-05-11",
      "last_synced_at": "2026-09-05T16:43:44.990Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • St. Petersburg, Florida • Marietta, Georgia + 5 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Arlington",
          "state": "Texas"
        },
        {
          "city": "Orem",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02132247"
    },
    {
      "nct_id": "NCT04375800",
      "title": "Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Human Immunodeficiency Virus (HIV) Infection"
      ],
      "interventions": [
        {
          "name": "Doravirine",
          "type": "DRUG"
        },
        {
          "name": "2 NRTIs",
          "type": "DRUG"
        },
        {
          "name": "DOR/3TC/TDF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Weeks",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "4 Weeks to 11 Years"
      },
      "enrollment_count": 84,
      "start_date": "2021-02-03",
      "completion_date": "2034-04-11",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-09-05T16:43:44.990Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Atlanta, Georgia",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04375800"
    },
    {
      "nct_id": "NCT00776009",
      "title": "Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Attention-Deficit/Hyperactivity Disorder (ADHD)"
      ],
      "interventions": [
        {
          "name": "Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 165,
      "start_date": "2008-10",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2011-06-08",
      "last_synced_at": "2026-09-05T16:43:44.990Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00776009"
    },
    {
      "nct_id": "NCT00479258",
      "title": "Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Inhaled insulin (Exubera)",
          "type": "DRUG"
        },
        {
          "name": "Subcutaneous Insulin (subject's prescribed)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 2,
      "start_date": "2007-10",
      "completion_date": "2007-10",
      "has_results": true,
      "last_update_posted_date": "2018-10-01",
      "last_synced_at": "2026-09-05T16:43:44.990Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00479258"
    },
    {
      "nct_id": "NCT00754052",
      "title": "Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Down Syndrome",
        "Cognitive Dysfunction"
      ],
      "interventions": [
        {
          "name": "Aricept (donepezil hydrochloride)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "11 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "11 Years to 17 Years"
      },
      "enrollment_count": 8,
      "start_date": "2008-09",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2018-04-23",
      "last_synced_at": "2026-09-05T16:43:44.990Z",
      "location_count": 2,
      "location_summary": "San Antonio, Texas • Herndon, Virginia",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Herndon",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00754052"
    },
    {
      "nct_id": "NCT04844606",
      "title": "A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ulcerative Colitis",
        "Ulcerative Colitis Chronic",
        "Inflammatory Bowel Diseases",
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Mirikizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "2 Years to 19 Years"
      },
      "enrollment_count": 150,
      "start_date": "2021-05-26",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-09-05T16:43:44.990Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Hartford, Connecticut • Atlanta, Georgia + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04844606"
    },
    {
      "nct_id": "NCT00002193",
      "title": "Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Amprenavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Glaxo Wellcome",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Months to 18 Years"
      },
      "enrollment_count": 210,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-09-05T16:43:44.990Z",
      "location_count": 2,
      "location_summary": "Fort Lauderdale, Florida • Memphis, Tennessee",
      "locations": [
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002193"
    }
  ]
}